Which evidence questions matter in a tirzepatide research-standard packet?

Answer first

A tirzepatide research-standard packet should identify the engineered sequence and lipidation context used for the expected molecular form, then distinguish chromatographic profile, intact mass, deeper sequence evidence, and composition measurements. The discovery and structural literature make clear that sequence and fatty-acid modification are central to the molecule's defined structure.

Reviewed Chemical LedgerTirzepatide

Molecular form represented39-residue modified peptide with a C-terminal amide and a C20 fatty-diacid side chain at Lys20

CAS number: 2023788-19-2
Molecular formula: C225H348N48O68
Average molecular weight: 4813.45 Da average molecular weight
Exact mass: 4812.5315671 Da

Reviewed peptide designationTirzepatide; Aib2, Aib13, Lys20 lipidated, C-terminal serinamide

Sequence representationIncludes stated terminal and modification notation

Y-Aib-EGTFTSDYSI-Aib-LDKIAQK[gamma-Glu-2xAEEA-C20 diacid]-AFVQWLIAGGPSSGAPPPS-NH2

Structural notes

Aib residues at positions 2 and 13
C20 fatty diacid attached through gamma-Glu and two AEEA units at Lys20
C-terminal serinamide at residue 39

Known Aliases / Code Names:TirzepatideLY3298176Dual GIP/GLP-1 Receptor Agonist

Field-level sources

PubChem CID 166567236: Tirzepatide

National Library of Medicine / PubChem · accessed 2026-08-03

Supports: name, cas, formula, weight, exactMass, aliases

FDA GSRS validated Tirzepatide substance record

FDA / NCATS Global Substance Registration System · accessed 2026-08-03

Supports: molecularForm, sequence, peptideDesignation, modifications

Where this framework helps

Research-standard and identity-reference planning
Analytical document review for a modified, longer peptide
Defining comparable evidence across tirzepatide research lots

Limits to keep visible

This page does not provide a lot result, specification, or supplier qualification.
It does not provide medical, dosing, formulation, or administration guidance.
Sequence-evidence feasibility depends on the laboratory method and material form.

Anchor the packet to the engineered molecular form

Document the sequence reference, non-standard residue or modification context, lipid-derived side chain, expected mass basis, and the form used by the analytical method. These fields should be explicit before evidence is compared.

Choose identity depth intentionally

Intact mass can support agreement with the expected whole-molecule form. When the project needs localization or sequence-level confidence, request an appropriate fragment or orthogonal workflow and state the expected interpretation depth.

Keep composition and lot comparison visible

Record salt-form context, water, counter-ion or other composition fields relevant to the protocol, together with the method and reporting basis used for continuity between lots.

Primary and official sources

References used for this page

LY3298176: From Discovery to Clinical Proof of ConceptMolecular Metabolism / PubMed
Structural Determinants of Dual Incretin Receptor Agonism by TirzepatidePNAS / PubMed
ICH Q2(R2): Validation of Analytical ProceduresInternational Council for Harmonisation

Visible FAQ

Questions research teams ask

Why is intact mass not the entire tirzepatide identity story?

A whole-molecule mass comparison supports the expected form but does not automatically localize every sequence feature or modification. The required evidence depth should follow the research question.

Should a packet state the lipidation context?

Yes. The defined molecular form includes modification context that affects the expected mass and structural record, so it should not be left implicit.

Does this dossier compare commercial suppliers?

No. It defines research evidence questions. Commercial pricing, ordering, and supplier selection belong to the separate PeptideSource commercial workflow.